Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.66 |
| ▸ | INSR | P06213 | 5/20 | 0.61 |
| ▸ | IGF1R | P08069 | 5/20 | 0.61 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22942870 | 1.00 | EGFR (0.66) | EGFRINSRIGF1RALK | |
| SCHEMBL22942225 | 0.99 | EGFR (0.67) | EGFRINSRIGF1RALK | |
| SCHEMBL22942144 | 0.94 | INSR (0.69) | EGFRINSRIGF1RALK | |
| SCHEMBL24816789 | 0.93 | EGFR (0.65) | EGFRINSRIGF1RALK | |
| SCHEMBL30105864 | 0.92 | EGFR (0.69) | EGFRINSRIGF1RALK | |
| SCHEMBL24940076 | 0.92 | EGFR (0.69) | EGFRINSRIGF1RALK | |
| SCHEMBL22942135 | 0.92 | EGFR (0.72) | EGFR | |
| SCHEMBL24940083 | 0.91 | EGFR (0.68) | EGFRINSRIGF1RALK | |
| SCHEMBL30105877 | 0.91 | EGFR (0.68) | EGFRINSRIGF1RALK | |
| SCHEMBL22942153 | 0.91 | EGFR (0.59) | EGFRINSRIGF1RALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114430740-A | EGFR inhibitor, composition and preparation method thereof | 贝达药业股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-114430740-B | EGFR inhibitors, compositions and methods of making the same | 贝达药业股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-114430740-A | EGFR inhibitor, composition and preparation method thereof | 贝达药业股份有限公司 | 2022-05-03 | — | — | CN | disclosed |